|
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. |
|
|
Honoraria - AstraZeneca/Daiichi Sankyo; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Mylan; Pierre Fabre; SERVIER |
Consulting or Advisory Role - Bristol-Myers Squibb; Enterome; Exeliom Biosciences |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Mylan; SERVIER; SERVIER |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chugai Pharma |
Consulting or Advisory Role - Hoosier Cancer Research Network; Kronos Bio; Mirati Therapeutics; Regeneron; Yiviva |
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical |
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst) |
|
|
Leadership - ICON Group; Lipotek |
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Madrigal Pharmaceuticals; Moderna Therapeutics; Novavax; Opthea; Orphazyme; Twist Bioscience; UniQure; Zogenix |
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; MSD Oncology; Specialised Therapeutics; Targovax; Viatris |
Consulting or Advisory Role - 1Globe Health Institute; Alloplex Biotherapeutics Inc; Center for Emerging & Neglected Diseases (CEND); Deciphera; FivePHusion; Genor BioPharma; Lisata; Merck Sharp & Dohme; NOUS Group; Novotech; Revolution Medicines; Specialised Therapeutics |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst) |
|
|
Honoraria - Amgen; AstraZeneca; Bayer; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER |
Speakers' Bureau - Merck Serono |
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; SERVIER |
|
|
Honoraria - Amgen; Bayer; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; MSD; Nordic Bioscience; Pierre Fabre; Roche |
Speakers' Bureau - Merck; Pierre Fabre; SERVIER |
Research Funding - Bayer; Merck; Roche; SERVIER |
|
|
Consulting or Advisory Role - Abbvie; ALX Oncology; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Taiho Pharmaceutical; Takeda; TERUMO; Zymeworks |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Honoraria - Amgen; AstraZeneca; Merck; MSD; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; SERVIER |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck; MSD; MSD Oncology; Nordic Bioscience; Novartis; Oncosil; Pierre Fabre; Roche; Servier/Pfizer; TERUMO |
Research Funding - Amgen (Inst); Merck (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Merck |
|
|
Stock and Other Ownership Interests - Oniria Therapeutics |
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Cardiff Oncology; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc; Tolremo |
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource |
|
|
Consulting or Advisory Role - Nordic Bioscience (Inst) |
|
|
Employment - Asklepios Kliniken |
Honoraria - Amgen; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; Ipsen; Merck Serono; Merck Sharp and Dome; Pierre Fabre; Roche/Genentech; SERVIER |
Consulting or Advisory Role - AstraZeneca; Bayer; Biocompatibles; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Terumo |
Research Funding - Oncolytics (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Boston Scientific |
(OPTIONAL) Uncompensated Relationships - ESMO; ESMO Open; European Organisation for Research and Treatment of Cancer (EORTC); German Cancer Society; German Society for Hematology and Medical Oncology |
|
|
Consulting or Advisory Role - AstraZeneca; Medison; MSD; Roche |
Travel, Accommodations, Expenses - Medison; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer Health; BridgeBio Pharma; Bristol-Myers Squibb Foundation/Janssen; Exact Sciences; Exelixis; Gilead Sciences; GlaxoSmithKline; Merck Sharp & Dohme; Pfizer |
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters |
|
|
Consulting or Advisory Role - Genor BioPharma |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Ground Truth Laboratories; Nordic Bioscience; Nordic Bioscience; Perspectum Diagnostics |
Research Funding - Almac Diagnostics (Inst); AstraZeneca (Inst); Merck KgAA (Inst); PsiOxus Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - patent pending |
|
|
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Merck Serono; Pierre Fabre; Roche/Genentech; Sanofi; Seagen; SERVIER; Ventana Medical Systems |
Consulting or Advisory Role - Amgen; Aptitude Health; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; Gilead Sciences; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Nordic Bioscience; Pierre Fabre; Seagen; SERVIER; Tesaro; Transgene |
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology |
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation; Gercor |
|
|
No Relationships to Disclose |